Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease

A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringans, Scott D., Ito, Jun, Stoll, Thomas, Winfield, Kaye, Phillips, Michael, Peters, Kirsten, Davis, Wendy A., Davis, Timothy M.E., Lipscombe, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988498/
https://www.ncbi.nlm.nih.gov/pubmed/29900119
http://dx.doi.org/10.1016/j.euprot.2016.12.001
_version_ 1783329295644491776
author Bringans, Scott D.
Ito, Jun
Stoll, Thomas
Winfield, Kaye
Phillips, Michael
Peters, Kirsten
Davis, Wendy A.
Davis, Timothy M.E.
Lipscombe, Richard J.
author_facet Bringans, Scott D.
Ito, Jun
Stoll, Thomas
Winfield, Kaye
Phillips, Michael
Peters, Kirsten
Davis, Wendy A.
Davis, Timothy M.E.
Lipscombe, Richard J.
author_sort Bringans, Scott D.
collection PubMed
description A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 572 patients. Five proteins were significantly associated with diabetic kidney disease defined by albuminuria, renal impairment (eGFR) and chronic kidney disease staging (CKD Stage ≥1, ROC curve of 0.77). The results prove the suitability and efficacy of the process used, and introduce a biomarker panel with the potential to improve diagnosis of diabetic kidney disease.
format Online
Article
Text
id pubmed-5988498
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-59884982018-06-13 Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease Bringans, Scott D. Ito, Jun Stoll, Thomas Winfield, Kaye Phillips, Michael Peters, Kirsten Davis, Wendy A. Davis, Timothy M.E. Lipscombe, Richard J. EuPA Open Proteom Regular Article A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 572 patients. Five proteins were significantly associated with diabetic kidney disease defined by albuminuria, renal impairment (eGFR) and chronic kidney disease staging (CKD Stage ≥1, ROC curve of 0.77). The results prove the suitability and efficacy of the process used, and introduce a biomarker panel with the potential to improve diagnosis of diabetic kidney disease. Elsevier 2017-01-05 /pmc/articles/PMC5988498/ /pubmed/29900119 http://dx.doi.org/10.1016/j.euprot.2016.12.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Bringans, Scott D.
Ito, Jun
Stoll, Thomas
Winfield, Kaye
Phillips, Michael
Peters, Kirsten
Davis, Wendy A.
Davis, Timothy M.E.
Lipscombe, Richard J.
Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
title Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
title_full Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
title_fullStr Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
title_full_unstemmed Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
title_short Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
title_sort comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988498/
https://www.ncbi.nlm.nih.gov/pubmed/29900119
http://dx.doi.org/10.1016/j.euprot.2016.12.001
work_keys_str_mv AT bringansscottd comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT itojun comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT stollthomas comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT winfieldkaye comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT phillipsmichael comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT peterskirsten comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT daviswendya comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT davistimothyme comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease
AT lipscomberichardj comprehensivemassspectrometrybasedbiomarkerdiscoveryandvalidationplatformasappliedtodiabetickidneydisease

Ejemplares similares